



Universiteit
Leiden
The Netherlands

New therapies for autoimmune myasthenia gravis: vol 22, pg 368, 2023

Verschuuren, J.

Citation

Verschuuren, J. (2023). New therapies for autoimmune myasthenia gravis: vol 22, pg 368, 2023. *The Lancet Neurology*, 22(6), E8-E8. doi:10.1016/S1474-4422(23)00173-4

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4248808>

Note: To cite this publication please use the final published version (if applicable).

**Correction to
Lancet Neurol 2023;
22: 368–69**

Verschuuren J. New therapies for autoimmune myasthenia gravis. Lancet Neurol 2023; 22: 368–69—In this Comment, the drug rozanolixizumab was misspelled twice. This correction has been made to the online version as of May 18, 2023.

**Correction to
Lancet Neurol 2023;
22: 373–74**

Duncan JS, Taylor PN. Optimising epilepsy surgery. Lancet Neurol 2023; 22: 373–74—In this Comment, the authors' declaration of interests statements were missing; the full declarations are now included. This correction has been made to the online version as of May 18, 2023.

**Correction to
Lancet Neurol 2023;
22: 505–16**

Sokolov E, Dietrich J, Cole AJ. The complexities underlying epilepsy in people with glioblastoma. Lancet Neurol 2023; 22: 505–16—In this Review, the Search strategy and selection criteria panel has been added. This correction has been made to the online version as of May 18, 2023, and the printed version is correct.